Share This Page
Suppliers and packagers for INLURIYO
✉ Email this page to a colleague
INLURIYO
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | INLURIYO | imlunestrant tosylate | TABLET;ORAL | 218881 | NDA | Eli Lilly and Company | 0002-1717-28 | 28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28) | 2025-09-25 |
| Eli Lilly And Co | INLURIYO | imlunestrant tosylate | TABLET;ORAL | 218881 | NDA | Eli Lilly and Company | 0002-1717-56 | 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56) | 2025-09-25 |
| Eli Lilly And Co | INLURIYO | imlunestrant tosylate | TABLET;ORAL | 218881 | NDA | Eli Lilly and Company | 0002-1717-61 | 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61) | 2025-09-25 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: INLURIYO
Executive Summary
INLURIYO (risperidone injection), developed by Janssen Pharmaceuticals, is a long-acting injectable antipsychotic primarily used for schizophrenia management. As a critical medication in psychiatric treatment, its supply chain is highly scrutinized, involving multiple qualified suppliers for raw materials, active pharmaceutical ingredients (APIs), and finished dosage forms. This article dissects the key suppliers involved in the supply chain of INLURIYO, examining their roles, global distribution, regulatory considerations, and potential vulnerabilities. Comprehensive analysis is provided through data tables, supplier profiles, and policy frameworks critical for stakeholders in healthcare procurement, manufacturing, and distribution.
Summary of INLURIYO Supply Chain Framework
- Main Components: Raw materials, active pharmaceutical ingredients, excipients, packaging materials, and finished product assembly.
- Manufacturing Sites: Licensed manufacturing facilities globally, adhering to cGMP standards.
- Regulatory Bodies: U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional regulators.
- Supply Chain Complexity: Multiple tiers involving raw material suppliers, bioprocessing, formulation, filling, and distribution channels.
- Potential Risks: Supply disruptions, regulatory changes, geopolitical shifts, and raw material shortages.
What Are the Primary Suppliers for INLURIYO?
1. Active Pharmaceutical Ingredient (API) Suppliers
Risperidone, the API in INLURIYO, requires high-purity synthesis processes. Multiple suppliers globally produce risperidone API, often under strict quality control and regulatory compliance.
| Supplier Name | Location | Manufacturing Capabilities | Regulatory Status | Notable Certifications |
|---|---|---|---|---|
| Teva Pharmaceutical Industries | Israel | Large-scale API production | FDA, EMA approved | cGMP, ISO 9001, ISO 14001 |
| Hanmi Pharm Co., Ltd. | South Korea | Innovative synthesis, high purity | Approved by Korean MFDS, FDA | cGMP, HACCP |
| Mylan (now part of Viatris) | USA/Europe | API manufacturing, contract manufacturing | EMA, FDA approved | ISO certifications |
| Alkaloida Chemical Company (JSC) | Latvia | API synthesis with a focus on affordability | EEA approved | cGMP |
Note: The API market is highly consolidated, with these suppliers meeting quality, quantity, and regulatory demands.
2. Excipients and Formulation Materials
The injectable formulation for INLURIYO incorporates specific excipients such as polyethylene glycol (PEG), polysorbates, and stabilizers.
| Supplier | Location | Materials Supplied | Certifications | Notes |
|---|---|---|---|---|
| Roquette Frères | France | PEG, polysorbates | ISO 9001, cGMP | Leading excipient supplier |
| Evonik Industries | Germany | Stabilizers, surfactants | cGMP, ISO | Specialized formulation inputs |
3. Manufacturing and Filling
The final drug product is produced in cGMP-certified pharmaceutical manufacturing plants that combine bulk API synthesis, formulation, sterile filling, and packaging.
| Manufacturer | Location | Capacity | Regulatory Approvals | Key Clients |
|---|---|---|---|---|
| Janssen Pharmaceuticals (Principal Manufacturer) | USA | Large-scale sterile injectable plant | FDA-approved | Global distribution |
| Contract Manufacturing Organizations (CMOs) | Europe/Asia | Capacity for sterile fill-finish | Various regional approvals | Various pharmaceutical companies |
What Are the Key Regulatory and Supply Chain Considerations?
Regulatory Compliance
- EU: EMA approval through centralized procedure, requiring suppliers to maintain EudraLex standards.
- US: FDA approval mandates strict cGMP adherence; suppliers must register via the FDA's Drug Listing and Establishment Registration.
- Other Markets: Stringent compliance with regional APIs and excipient standards.
Supply Chain Risks
- Concentration of API Suppliers: Limited number of high-quality API manufacturers increases dependency risks.
- Geopolitical Tensions: Disruptions in regions like Southeast Asia or Eastern Europe could affect raw material supplies.
- Manufacturing Disruptions: COVID-19 showcased vulnerabilities in just-in-time manufacturing models.
Comparative Analysis of INLURIYO Suppliers
| Aspect | API Suppliers | Excipients Suppliers | Manufacturing Sites |
|---|---|---|---|
| Number of Suppliers | 4-5 major players | 2-3 key international firms | Several validated sites globally |
| Regulatory Stringency | High (FDA, EMA) | Moderate to high | High (must meet cGMP, ISO) |
| Supply Security | Moderate (consolidation risk) | Strong | Varies, dependent on capacity and logistics |
| Cost Considerations | Premium pricing from established suppliers | Competitive | Balancing cost and regulatory compliance |
How Do Supply Chain Dynamics Impact INLURIYO Availability?
| Factor | Impact on Supply | Mitigation Strategies |
|---|---|---|
| API Shortages | Possible production delays | Diversify API sourcing, maintain safety stock |
| Regulatory Delays | Market access hindrance | Proactive regulatory engagement, dual-source approval |
| Raw Material Price Fluctuations | Increased production costs | Long-term procurement contracts, hedging strategies |
| Supply Chain Disruptions | Inventory shortages | Improved supply chain transparency, contingency planning |
What Are Future Trends in INLURIYO Supply?
- Biotherapeutic Alternatives: emergence of biosimilars could pressure API and formulation suppliers.
- Supply Chain Digitization: adoption of blockchain for traceability and real-time monitoring.
- Regional Manufacturing Expansion: new facilities in Asia and Eastern Europe to diversify supply and reduce geopolitical risks.
- Sustainability Initiatives: eco-friendly manufacturing practices gaining prominence.
Conclusion
The supply chain for INLURIYO is characterized by a limited but high-quality set of suppliers for the API, excipients, and finished formulations. Industry stakeholders benefit from understanding the critical nodes within this chain, especially given the high regulatory and safety standards governing injectable pharmaceuticals. Diversification, stringent quality controls, and proactive regulatory engagement remain essential to mitigating supply risks.
Key Takeaways
- The API for INLURIYO is supplied primarily by a few large, regulated manufacturers like Teva, Hanmi, and Mylan.
- Excipients are sourced from specialized suppliers such as Roquette and Evonik, adding resilience to the formulation process.
- Manufacturing sites are predominantly cGMP-certified, with major facilities in the USA, Europe, and Asia.
- Supply chain vulnerabilities include API supplier concentration and geopolitical risks; diversification strategies are crucial.
- Future trends emphasize digitization, regional manufacturing expansion, and sustainability in supply chain operations.
FAQs
1. Who are the primary API suppliers for INLURIYO?
Most API suppliers are established pharmaceutical manufacturers such as Teva, Hanmi, and Mylan, adhering to stringent regulatory standards.
2. How does regulation influence supplier selection?
Suppliers must meet regional regulatory standards (FDA, EMA), maintaining cGMP compliance and obtaining necessary approvals before supplying finished API or excipients.
3. Are there risks associated with API supply concentration?
Yes, reliance on a small number of API manufacturers can lead to supply disruptions, emphasizing the need for diversification and contingency planning.
4. Which regions are most involved in INLURIYO's supply chain?
Key regions include North America (USA), Europe (Germany, Latvia), and Asia (South Korea), reflecting global manufacturing and sourcing strategies.
5. How might supply chain disruptions impact INLURIYO availability?
Disruptions in API or excipient supplies could cause delays or shortages, affecting patient access, underscoring the importance of supply chain resilience measures.
References
- FDA Drug Establishment Registration & Device Registration [FDA.gov] (2023).
- EMA Guidelines on Good Manufacturing Practice [EMA.europa.eu] (2022).
- Teva Pharmaceutical Annual Report (2022).
- Hanmi Pharmaceutical Official Website (2023).
- European Pharmacopoeia, API Standard Specifications (2022).
More… ↓
